PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corp.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, PROCEPT BioRobotics Corp. has 57.25M shares outstanding.

As of June 30, 2026, PROCEPT BioRobotics Corp. maintains a current ratio of 6.55, meaning it holds 6.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.79, indicating elevated leverage, while an interest coverage ratio of -30.86 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, PROCEPT BioRobotics Corp. posted a negative return on equity (ROE) of -30.24, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -22.12, reflecting losses generated across the asset base. The company generates approximately 318,729.09 in revenue per employee across its workforce of 855.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.68 indicates how many times PROCEPT BioRobotics Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, PROCEPT BioRobotics Corp. recorded 41,199.33 in income tax expense. The company reported a pretax loss of -88.47M and -88.66M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, PROCEPT BioRobotics Corp. generated 272.51M in revenue and converted that into -88.66M in net income, yielding earnings per share of -1.57. EBITDA reached -86.58M, while operating income came in at -92.28M.

As of June 30, 2026, PROCEPT BioRobotics Corp. holds 184.12M in cash and equivalents against 62.61M in total debt, resulting in a net debt position of -142.34M. Total book value stands at 274.72M, with working capital of 287.66M providing operational flexibility.

PROCEPT BioRobotics Corp. produced -60.05M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -8.55M in capital expenditures, free cash flow totaled -68.60M - equivalent to -1.22 per share.

Over the twelve months ended June 30, 2026, PROCEPT BioRobotics Corp. posted a gross margin of 64.22, reflecting its pricing power and cost economics. The operating margin of -33.86 and net profit margin of -32.54 provide insight into operational efficiency.